Rituxan rituximab chimeric monoclonal antibody against CD20: Marketed

IDPH presented one-year follow-up data from 166 patients treated in its Phase III trial. Participants received 375

Read the full 175 word article

How to gain access

Continue reading with a
two-week free trial.